Why is Semaglutide Your Weight Loss Solution?
Semaglutide is a groundbreaking glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized weight management and diabetes treatment.
Originally developed for type 2 diabetes, its remarkable weight loss effects have made it the go-to choice for sustainable, medically-supervised weight management.
​​
​
Patient Success Story:
"After struggling with weight for years, Semaglutide finally gave me the control I needed. I've lost 38 pounds and kept it off for over a year." - Michael R.
​
​
Mechanism of Action
-
Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells
-
Glucagon Suppression: Reduces glucagon secretion from pancreatic alpha cells when glucose levels are elevated
-
Gastric Emptying: Slows gastric emptying, promoting satiety and reducing post-meal glucose spikes
-
Central Appetite Control: Acts on hypothalamic receptors to reduce appetite and food intake
-
Beta Cell Preservation: May help preserve pancreatic beta cell function
​
Life-Changing Benefits
​
Diabetes Benefits:
-
HbA1c reduction of 1.0-1.8%
-
Reduced fasting glucose levels
-
Lower postprandial glucose excursions
-
Cardiovascular risk reduction
-
Low hypoglycemia risk
​
Weight Management Success:
-
Average weight loss of 12-15% in clinical trials
-
Sustained weight reduction over 68 weeks
-
Improved body composition
-
Reduced visceral adiposity
-
Better weight maintenance
Clinical Excellence:
The STEP clinical trial program demonstrated that 86% of patients achieved at least 5% weight loss, with many achieving transformational results of 15% or more.
​
​
Dosing and Administration
​
Injectable Form:
Rotate injection site (abdomen, thigh or back of arm) with each injection.
​
Oral Form (coming soon):
​
Administration: Take on empty stomach with ≤4 oz water, 30 minutes before first food/drink/medication of the day
​
​
Side Effects
​
Common (≥5%):
-
Nausea (15-20%)
-
Vomiting (5-9%)
-
Diarrhea (8-9%)
-
Abdominal pain (5-7%)
-
Constipation (3-7%)
-
Headache (5-6%)
-
Fatigue (3-5%)
​
Serious (Rare):
-
Acute pancreatitis
-
Gallbladder disease
-
Acute kidney injury
-
Diabetic retinopathy complications
-
Severe hypoglycemia (with insulin/sulfonylureas)
-
Thyroid C-cell tumors (animal studies)
​
Drug Interactions
-
Insulin and Insulin Secretagogues: Increased risk of hypoglycemia; dose reduction may be needed
-
Oral Medications: May delay absorption due to delayed gastric emptying
-
Warfarin: Monitor INR more frequently when initiating semaglutide
-
Oral Contraceptives: Use alternative contraceptive method for 4 weeks after starting or dose increases
​
Monitoring Parameters
-
Blood Glucose: Regular monitoring, especially when combined with other diabetes medications
-
HbA1c: Every 3-6 months
-
Weight and BMI: Regular monitoring for weight management indication
-
Renal Function: Baseline and periodic monitoring
-
Signs of Pancreatitis: Educate patients on symptoms
-
Diabetic Retinopathy: Regular ophthalmologic examinations​​
​
​
Disclaimer: Not Medical Advice
​
The information provided herein is for informational and educational purposes only and is not intended as, nor should it be construed as, medical advice, diagnosis, or treatment. Nothing contained in this content, platform, communication, or related materials should be considered a substitute for professional medical advice, diagnosis, or treatment from a licensed healthcare provider. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read, heard, or accessed through this platform. Reliance on any information provided is solely at your own risk.